GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » NonCurrent Deferred Liabilities

KYTX (Kyverna Therapeutics) NonCurrent Deferred Liabilities : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Kyverna Therapeutics's non-current deferred liabilities for the quarter that ended in Jun. 2024 was $0.00 Mil.

Kyverna Therapeutics NonCurrent Deferred Liabilities Historical Data

The historical data trend for Kyverna Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics NonCurrent Deferred Liabilities Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
1.03 - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only - - - - -

Kyverna Therapeutics NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics Headlines